CoChat

Dominant Role of Oncogene Dosage and Absence of Tumor Suppressor Activity in Nras- Driven Hematopoietic Transformation

Open access
Xu, Jin, Haigis, Kevin M., Firestone, Ari J., McNerney, Megan E., Li, Qing, Davis, Elizabeth, Chen, Shann-Ching, Nakitandwe, Joy, Downing, James, Jacks, Tyler, Le Beau, Michelle M., Shannon, Kevin · 2013 · Cancer Discovery
Cited by 68

The DOI matches its Crossref record; 6 of the 6 references it cites were found in a registry or an index.

Abstract

Biochemical properties of Ras oncoproteins and their transforming ability strongly support a dominant mechanism of action in tumorigenesis. However, genetic studies unexpectedly suggested that wild-type (WT) Ras exerts tumor suppressor activity. Expressing oncogenic NrasG12D in the hematopoietic compartment of mice induces an aggressive myeloproliferative neoplasm that is exacerbated in homozygous mutant animals. Here, we show that increased NrasG12D gene dosage, but not inactivation of WT Nras, underlies the aggressive in vivo behavior of NrasG12D/G12D hematopoietic cells. Modulating NrasG12D dosage had discrete effects on myeloid progenitor growth, signal transduction, and sensitivity to MAP-ERK kinase (MEK) inhibition. Furthermore, enforced WT N-Ras expression neither suppressed the growth of Nras-mutant cells nor inhibited myeloid transformation by exogenous NrasG12D. Importantly, NRAS expression increased in human cancer cell lines with NRAS mutations. These data have therapeutic implications and support reconsidering the proposed tumor suppressor activity of WT Ras in other cancers. Significance: Understanding the mechanisms of Ras-induced transformation and adaptive cellular responses is fundamental. The observation that oncogenic Nras lacks tumor suppressor activity, whereas increased dosage strongly modulates cell growth and alters sensitivity to MEK inhibition, suggests new therapeutic opportunities in cancer. Cancer Discov; 3(9); 993–1001. ©2013 AACR. This article is highlighted in the In This Issue feature, p. 953

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1158/2159-8290.cd-13-0096

Cites

6 of 6 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 6 references

Cited by

See all 68

Metadata

Authors
Xu, J., Haigis, K. M., Firestone, A. J., McNerney, M. E., Li, Q., Davis, E., Chen, S.-C., Nakitandwe, J., Downing, J., Jacks, T., Le Beau, M. M., & Shannon, K.
Venue
Cancer Discovery
Published
2013-09-01
Volume
3
Issue
9
Pages
993-1001
ISSN
  • 2159-8274 (ISSN-L)
  • 2159-8290
OpenAlex
W2155586760
Cited by
68
References
6
FWCI
3.36
Type
journal article
Language
en
Open access
green

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Dominant Role of Oncogene Dosage and Absence of Tumor Suppressor Activity in Nras- Driven Hematopoietic Transformation. https://app.cochat.ai/papers/10.1158/2159-8290.cd-13-0096
The paper
Xu, J., Haigis, K. M., Firestone, A. J., McNerney, M. E., Li, Q., Davis, E., Chen, S.-C., Nakitandwe, J., Downing, J., Jacks, T., Le Beau, M. M., & Shannon, K. (2013). Dominant Role of Oncogene Dosage and Absence of Tumor Suppressor Activity in Nras- Driven Hematopoietic Transformation. Cancer Discovery. https://doi.org/10.1158/2159-8290.cd-13-0096

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.